1. Home
  2. M vs CRSP Comparison

M vs CRSP Comparison

Compare M & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Macy's Inc

M

Macy's Inc

HOLD

Current Price

$23.35

Market Cap

6.7B

ML Signal

HOLD

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$60.35

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
M
CRSP
Founded
1830
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
5.9B
IPO Year
2003
2016

Fundamental Metrics

Financial Performance
Metric
M
CRSP
Price
$23.35
$60.35
Analyst Decision
Hold
Buy
Analyst Count
13
17
Target Price
$20.09
$70.29
AVG Volume (30 Days)
6.3M
1.5M
Earning Date
05-27-2026
05-11-2026
Dividend Yield
3.97%
N/A
EPS Growth
12.08
N/A
EPS
0.23
N/A
Revenue
$22,621,000,000.00
$289,590,000.00
Revenue This Year
N/A
$807.72
Revenue Next Year
N/A
$172.52
P/E Ratio
$102.89
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$11.77
$44.12
52 Week High
$26.10
$78.48

Technical Indicators

Market Signals
Indicator
M
CRSP
Relative Strength Index (RSI) 49.62 64.11
Support Level $21.80 $47.48
Resistance Level $24.22 $75.06
Average True Range (ATR) 0.91 3.22
MACD -0.33 0.81
Stochastic Oscillator 12.01 74.32

Price Performance

Historical Comparison
M
CRSP

About M Macy's Inc

Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: